STE — STERIS plc

Summary of STERIS plc Q3 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: Grew 9% year-over-year; constant currency organic revenue increased by 8%.
• Gross Margin: Declined by 70 basis points to 43.9%, primarily due to increased tariffs and inflation.
• EBIT Margin: Decreased by 40 basis points to 22.9%.
• Adjusted Net Income: $249.4 million; earnings per diluted share rose 9% to $2.53.
• Free Cash Flow: $7.368 billion for the first nine months of fiscal 2026.
• Debt: Total debt stood at $1.9 billion, with a gross debt to EBITDA ratio of approximately 1.2.

2. Strategic Updates and Business Highlights

• Healthcare Segment: Constant currency organic revenue grew 8%, with service revenue up 11%. Capital equipment revenue increased by 7%, with backlog remaining over $400 million.
• AST Segment: Revenue also grew 8%, with services up 9% and capital equipment revenue soaring 103%. EBIT margins improved to 45.1%.
• Life Sciences: Constant currency organic revenue increased by 5%, driven by an 11% growth in consumables.
• Tariff Impact: Approximately $16 million in pretax tariff impact noted, primarily affecting the healthcare segment.

3. Forward Guidance and Outlook

• Fiscal 2026 Revenue Growth: Maintaining guidance of 8% to 9% as-reported revenue growth and 7% to 8% constant currency organic revenue growth.
• Earnings Outlook: Expected earnings per share between $10.00 and $10.30, with the higher end less likely due to anticipated tariff increases.
• Free Cash Flow: Expected to be $850 million, with capital expenditures unchanged at $375 million.

4. Bad News, Challenges, or Points of Concern

• Gross Margin Decline: The decline in gross margin due to tariffs and inflation is a significant concern.
• Tariff Headwinds: An increase of $10 million in anticipated tariffs could impact profitability.
• Order Trends: Orders in the healthcare segment are down 1% year-to-date, indicating potential challenges in maintaining growth momentum.
• Market Comparisons: The fourth quarter faces tough year-over-year comparisons, particularly in the AST segment, which had a strong prior year.

5. Notable Q&A Insights

• Fourth Quarter Growth Concerns: Management expressed caution regarding fourth-quarter growth, anticipating a slowdown in comparison to the previous year.
• Capital Equipment Backlog: The healthcare backlog remains stable, while life sciences backlog shows strong growth due to increased pharmaceutical spending.
• Tariff Mitigation Efforts: The company is actively pursuing various strategies to mitigate tariff impacts, including supplier negotiations and operational efficiencies.
• Market Conditions: Positive macroeconomic conditions are noted, particularly in life sciences, with potential growth from US onshoring efforts.
• Acquisition Strategy: While STERIS has been active in smaller acquisitions, management remains disciplined about larger transformative deals, indicating a cautious approach to M&A.

This summary encapsulates the key points from the earnings call, highlighting STERIS's financial performance, strategic initiatives, and challenges ahead.